共 48 条
[1]
Viigimaa M(2020)Macrovascular Complications of Type 2 Diabetes Mellitus Curr Vasc Pharmacol 18 110-116
[2]
Sachinidis A(2020)Diabetes Mellitus and Acute Coronary Syndrome: A Lethal Combination Requiring Better Therapeutic Strategies Curr Vasc Pharmacol 18 77-79
[3]
Toumpourleka M(2019)Ticagrelor or Prasugrel in Patients with Acute Coronary Syndromes N Engl J Med 381 1524-1534
[4]
Koutsampasopoulos K(2020)Ticagrelor or Prasugrel in Patients With Acute Coronary Syndromes and Diabetes Mellitus JACC Cardiovasc Interv 13 2238-2247
[5]
Alliksoo S(2010)Critical Evaluation of the Newcastle-Ottawa Scale for the Assessment of the Quality of Nonrandomized Studies in Meta-Analyses Eur J Epidemiol 25 603-605
[6]
Titma T(2020)The PRISMA Statement: An Updated Guideline for Reporting Systematic Reviews BMJ 2021 5546260-240
[7]
Katsiki N(2021)Clinical Outcome between Ticagrelor versus Clopidogrel in Patients with Acute Coronary Syndrome and Diabetes Cardiovasc Ther 2021 234-318
[8]
Papanas N(2019)Analysis of Ticagrelor's Cardio-Protective Effects on Patients with ST-Segment Elevation Acute Coronary Syndrome Accompanied with Diabetes Open Med (Wars) 14 312-1229
[9]
Schüpke S(2019)Therapy with Ticagrelor for ST-Elevated Acute Coronary Syndrome Accompanied by Diabetes Mellitus Eur Rev Med Pharmacol Sci 23 1221-1502
[10]
Neumann F-J(2020)Platelet Inhibition with Ticagrelor versus Clopidogrel in Diabetic Patients after Percutaneous Coronary Intervention for Chronic Coronary Syndromes Thromb Haemost 120 1500-837